Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ENTX 
Entera Bio Ltd (ENTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ENTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.62% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 127.86M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.69 | 52 Weeks Range 1.50 - 3.11 | Updated Date 11/4/2025 |
52 Weeks Range 1.50 - 3.11 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.16 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6378.92% |
Management Effectiveness
Return on Assets (TTM) -44.56% | Return on Equity (TTM) -82.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 75192156 | Price to Sales(TTM) 770.23 |
Enterprise Value 75192156 | Price to Sales(TTM) 770.23 | ||
Enterprise Value to Revenue 452.96 | Enterprise Value to EBITDA -1.52 | Shares Outstanding 45663381 | Shares Floating 28765647 |
Shares Outstanding 45663381 | Shares Floating 28765647 | ||
Percent Insiders 24.31 | Percent Institutions 22.36 |
Upturn AI SWOT
Entera Bio Ltd
Company Overview
History and Background
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need. Founded in 2010, the company's focus is on osteoporosis and hypoparathyroidism.
Core Business Areas
- Oral Delivery Technology: Entera Bio's core technology involves developing oral formulations for large molecules, traditionally administered via injection or infusion. This enhances patient convenience and compliance.
- Osteoporosis Treatment: Development of oral parathyroid hormone (PTH) as a treatment for osteoporosis.
- Hypoparathyroidism Treatment: Development of oral PTH for the treatment of hypoparathyroidism.
Leadership and Structure
Entera Bio's leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure is typical of a clinical-stage biotech company, focusing on R&D, clinical development, and regulatory affairs.
Top Products and Market Share
Key Offerings
- EB613 (Oral PTH for Osteoporosis): Entera Bio's lead product candidate is EB613, an oral formulation of parathyroid hormone (PTH) for the treatment of osteoporosis. It is currently in clinical development. Competitors include injectable PTH therapies like Eli Lilly's Forteo and Amgen's Prolia. Market share data is not applicable as EB613 is not yet approved.
- EB612 (Oral PTH for Hypoparathyroidism): Entera Bio's oral PTH formulation aimed at treating hypoparathyroidism. It is in early clinical stages. The main competitor is Takeda's Natpara (injectable PTH 1-84). Market share data is not applicable as EB612 is not yet approved.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and strong competition. The osteoporosis and hypoparathyroidism markets are dominated by established injectable therapies, but there is a growing demand for oral alternatives.
Positioning
Entera Bio aims to disrupt the osteoporosis and hypoparathyroidism treatment landscape by providing convenient oral alternatives to injectable therapies. Its competitive advantage lies in its proprietary oral delivery technology.
Total Addressable Market (TAM)
The TAM for osteoporosis and hypoparathyroidism treatments is estimated to be in the billions of dollars. Entera Bio is positioned to capture a significant share of this market if its oral PTH therapies are successfully developed and commercialized.
Upturn SWOT Analysis
Strengths
- Proprietary oral delivery technology
- Potential to disrupt established injectable markets
- Experienced management team
- Focus on areas with unmet medical need
Weaknesses
- Clinical stage company with no approved products
- High R&D costs and risk of clinical trial failure
- Reliance on successful development and commercialization of oral PTH
- Limited financial resources
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of oral delivery technology to other therapeutic areas
- Positive clinical trial results
- Growing demand for convenient oral therapies
Threats
- Competition from established injectable therapies
- Regulatory hurdles and delays
- Clinical trial failures
- Generic competition if oral PTH is successfully commercialized
Competitors and Market Share
Key Competitors
- LLY
- AMGN
- TAK
Competitive Landscape
Entera Bio faces significant competition from established injectable therapies. Its competitive advantage lies in its oral delivery technology, which could offer greater convenience and compliance.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth as a clinical-stage company. Growth potential is dependent on successful development and commercialization of oral PTH.
Future Projections: Future growth projections are based on analyst estimates, which are highly uncertain and dependent on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for EB613 and EB612, securing partnerships, and raising capital.
Summary
Entera Bio is a clinical-stage biopharmaceutical company with promising oral delivery technology. The company's success hinges on the successful development and commercialization of its oral PTH therapies. While there is great opportunity and market value, Entera Bio must face the risks inherent in pharmaceutical development, including potential clinical trial failures and regulatory hurdles.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entera Bio Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-06-28 | CEO & Director Ms. Miranda J. Toledano M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://www.enterabio.com |
Full time employees 19 | Website https://www.enterabio.com | ||
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.